aica ribonucleotide has been researched along with Myotonic Dystrophy in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Jasmin, BJ; Misquitta, NS; Ravel-Chapuis, A | 1 |
Al-Rewashdy, A; Bélanger, G; Jasmin, BJ; Ravel-Chapuis, A | 1 |
Angelini, C; Brockhoff, M; Castets, P; Chojnowska, K; Eickhorst, C; Erne, B; Frank, S; Furling, D; Rion, N; Rüegg, MA; Sinnreich, M; Wiktorowicz, T | 1 |
3 other study(ies) available for aica ribonucleotide and Myotonic Dystrophy
Article | Year |
---|---|
Combinatorial treatment with exercise and AICAR potentiates the rescue of myotonic dystrophy type 1 mouse muscles in a sex-specific manner.
Topics: AMP-Activated Protein Kinases; Animals; Female; Male; Mice; Muscle, Skeletal; Myotonic Dystrophy; Physical Conditioning, Animal; Ribonucleotides | 2023 |
Pharmacological and physiological activation of AMPK improves the spliceopathy in DM1 mouse muscles.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; Animals; Disease Models, Animal; Humans; Mice; Motor Activity; Muscle, Skeletal; Myoblasts; Myotonic Dystrophy; Protein Kinases; Resveratrol; Ribonucleotides; RNA-Binding Proteins; RNA, Messenger; Trinucleotide Repeat Expansion | 2018 |
Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I.
Topics: Adult; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Disease Models, Animal; Female; Humans; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Mutant Strains; Middle Aged; Multiprotein Complexes; Muscle Fibers, Skeletal; Muscle Relaxation; Myotonic Dystrophy; Myotonin-Protein Kinase; Ribonucleotides; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2017 |